[Nle4, D-Phe7]-α-Melanocyte Stimulating Hormone trifluoroacetate salt - ≥95% (HPLC), high purity , CAS No.75921-69-6, Agonist of MC 1 receptor;Agonist of MC 3 receptor;Agonist of MC 4 receptor;Agonist of MC 5 receptor

Item Number
N118984
Grouped product items
SKUSizeAvailabilityPrice Qty
N118984-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$155.90
N118984-5mg
5mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$547.90
N118984-25mg
25mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$2,466.90
N118984-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$8,877.90

Melanocortin receptor agonist

Basic Description

Synonyms[Nle4,D-Phe7]-a-MSH | Msh, 4-nle-7-phe-alpha- | AC-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 | alpha-Melanotropin, 4-L-norleucine-7-D-phenylalanine- | CUV 1647 | Melanotan-1 | 4-Nle-7-phe-alpha-msh | .ALPHA.-MELANOTROPIN (SWINE), 4-L-NORLE
Specifications & PurityMoligand™, ≥95%(HPLC)
Biochemical and Physiological MechanismsSynthetic analog ofα-MSH that is an agonist at melanocortin receptors (Kivalues are 0.085, 0.4, 3.8 and 5.1 nM for MC1, MC3, MC4and MC5receptors respectively).
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeAGONIST
Mechanism of actionAgonist of MC 1 receptor;Agonist of MC 3 receptor;Agonist of MC 4 receptor;Agonist of MC 5 receptor
Note1mg卖完停产,不再备货
Product Description

Amino Acid Sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2

Associated Targets(Human)

MC5R Tchem Melanocortin receptor 5 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
MC4R Tclin Melanocortin receptor 4 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
MC3R Tchem Melanocortin receptor 3 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
MC1R Tclin Melanocyte-stimulating hormone receptor (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
INCHI InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)/t52-,53-,54-,55-,56+,57-,58-,59-,60-,61-,62-,65-/m0/s1
InChi Key UAHFGYDRQSXQEB-LEBBXHLNSA-N
Canonical SMILES CCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)C)C(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CO)NC(=O)C
Isomeric SMILES CCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N5CCC[C@H]5C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)C
PubChem CID 16154396
Molecular Weight 1646.85

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

5 results found

Lot NumberCertificate TypeDateItem
L1811159Certificate of AnalysisSep 20, 2022 N118984
L1811158Certificate of AnalysisSep 20, 2022 N118984
I1428026Certificate of AnalysisJul 19, 2022 N118984
G1809007Certificate of AnalysisMay 13, 2022 N118984
G1809006Certificate of AnalysisMay 13, 2022 N118984

Chemical and Physical Properties

SolubilitySoluble to 0.60 (mg/mL) in water}

Related Documents

References

1. Minder EI, Barman-Aksoezen J, Schneider-Yin X.  (2017)  Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders..  Clin Pharmacokinet,  56  (8): (815-823).  [PMID:28063031] [10.1021/op500134e]
2. Kim ES, Garnock-Jones KP.  (2016)  Afamelanotide: A Review in Erythropoietic Protoporphyria..  Am J Clin Dermatol,  17  (2): (179-85).  [PMID:26979527] [10.1021/op500134e]
3. Luger TA, Böhm M.  (2015)  An α-MSH analog in erythropoietic protoporphyria..  J Invest Dermatol,  135  (4): (929-931).  [PMID:25785940] [10.1021/op500134e]
4. McNeil MM, Nahhas AF, Braunberger TL, Hamzavi IH.  (2018)  Afamelanotide in the Treatment of Dermatologic Disease.  Skin Therapy Lett,  23  (6): (6-10).  [PMID:30517779] [10.1021/op500134e]

Solution Calculators